132 related articles for article (PubMed ID: 26995279)
1. The antiproliferative and proapoptotic effects of cladosporols A and B are related to their different binding mode as PPARγ ligands.
Zurlo D; Ziccardi P; Votino C; Colangelo T; Cerchia C; Dal Piaz F; Dallavalle S; Moricca S; Novellino E; Lavecchia A; Colantuoni V; Lupo A
Biochem Pharmacol; 2016 May; 108():22-35. PubMed ID: 26995279
[TBL] [Abstract][Full Text] [Related]
2. Cladosporol a stimulates G1-phase arrest of the cell cycle by up-regulation of p21(waf1/cip1) expression in human colon carcinoma HT-29 cells.
Zurlo D; Leone C; Assante G; Salzano S; Renzone G; Scaloni A; Foresta C; Colantuoni V; Lupo A
Mol Carcinog; 2013 Jan; 52(1):1-17. PubMed ID: 22025467
[TBL] [Abstract][Full Text] [Related]
3. Cladosporol A, a new peroxisome proliferator-activated receptor γ (PPARγ) ligand, inhibits colorectal cancer cells proliferation through β-catenin/TCF pathway inactivation.
Zurlo D; Assante G; Moricca S; Colantuoni V; Lupo A
Biochim Biophys Acta; 2014 Jul; 1840(7):2361-72. PubMed ID: 24735796
[TBL] [Abstract][Full Text] [Related]
4. Cladosporols A and B, two natural peroxisome proliferator-activated receptor gamma (PPARγ) agonists, inhibit adipogenesis in 3T3-L1 preadipocytes and cause a conditioned-culture-medium-dependent arrest of HT-29 cell proliferation.
Rapuano R; Ziccardi P; Cioffi V; Dallavalle S; Moricca S; Lupo A
Biochim Biophys Acta Gen Subj; 2021 Nov; 1865(11):129973. PubMed ID: 34352342
[TBL] [Abstract][Full Text] [Related]
5. Proliferation and migration of PC-3 prostate cancer cells is counteracted by PPARγ-cladosporol binding-mediated apoptosis and a decreased lipid biosynthesis and accumulation.
Rapuano R; Riccio A; Mercuri A; Madera JR; Dallavalle S; Moricca S; Lupo A
Biochem Pharmacol; 2024 Apr; 222():116097. PubMed ID: 38428827
[TBL] [Abstract][Full Text] [Related]
6. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
Lin MS; Chen WC; Bai X; Wang YD
J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
[TBL] [Abstract][Full Text] [Related]
7. Chiral phenoxyacetic acid analogues inhibit colon cancer cell proliferation acting as PPARγ partial agonists.
Sabatino L; Ziccardi P; Cerchia C; Muccillo L; Piemontese L; Loiodice F; Colantuoni V; Lupo A; Lavecchia A
Sci Rep; 2019 Apr; 9(1):5434. PubMed ID: 30931956
[TBL] [Abstract][Full Text] [Related]
8. Cladosporol A triggers apoptosis sensitivity by ROS-mediated autophagic flux in human breast cancer cells.
Koul M; Kumar A; Deshidi R; Sharma V; Singh RD; Singh J; Sharma PR; Shah BA; Jaglan S; Singh S
BMC Cell Biol; 2017 Jul; 18(1):26. PubMed ID: 28728544
[TBL] [Abstract][Full Text] [Related]
9. Simvastatin induces cell cycle arrest and inhibits proliferation of bladder cancer cells via PPARγ signalling pathway.
Wang G; Cao R; Wang Y; Qian G; Dan HC; Jiang W; Ju L; Wu M; Xiao Y; Wang X
Sci Rep; 2016 Oct; 6():35783. PubMed ID: 27779188
[TBL] [Abstract][Full Text] [Related]
10. 4-O-methylhonokiol, a PPARγ agonist, inhibits prostate tumour growth: p21-mediated suppression of NF-κB activity.
Lee NJ; Oh JH; Ban JO; Shim JH; Lee HP; Jung JK; Ahn BW; Yoon DY; Han SB; Ham YW; Hong JT
Br J Pharmacol; 2013 Mar; 168(5):1133-45. PubMed ID: 23043610
[TBL] [Abstract][Full Text] [Related]
11. PPARγ-dependent pathway in the growth-inhibitory effects of K562 cells by carotenoids in combination with rosiglitazone.
Zhao H; Gu H; Zhang H; Li JH; Zhao WE
Biochim Biophys Acta; 2014 Jan; 1840(1):545-55. PubMed ID: 24036327
[TBL] [Abstract][Full Text] [Related]
12. Deoxyelephantopin inhibits cancer cell proliferation and functions as a selective partial agonist against PPARgamma.
Zou G; Gao Z; Wang J; Zhang Y; Ding H; Huang J; Chen L; Guo Y; Jiang H; Shen X
Biochem Pharmacol; 2008 Mar; 75(6):1381-92. PubMed ID: 18164690
[TBL] [Abstract][Full Text] [Related]
13. A compound-based proteomic approach discloses 15-ketoatractyligenin methyl ester as a new PPARγ partial agonist with anti-proliferative ability.
Vasaturo M; Fiengo L; De Tommasi N; Sabatino L; Ziccardi P; Colantuoni V; Bruno M; Cerchia C; Novellino E; Lupo A; Lavecchia A; Piaz FD
Sci Rep; 2017 Jan; 7():41273. PubMed ID: 28117438
[TBL] [Abstract][Full Text] [Related]
14. The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines.
Morosetti R; Servidei T; Mirabella M; Rutella S; Mangiola A; Maira G; Mastrangelo R; Koeffler HP
Int J Oncol; 2004 Aug; 25(2):493-502. PubMed ID: 15254749
[TBL] [Abstract][Full Text] [Related]
15. A role for peroxisome proliferator-activated receptor gamma in resveratrol-induced colon cancer cell apoptosis.
Aires V; Brassart B; Carlier A; Scagliarini A; Mandard S; Limagne E; Solary E; Martiny L; Tarpin M; Delmas D
Mol Nutr Food Res; 2014 Sep; 58(9):1785-94. PubMed ID: 24975132
[TBL] [Abstract][Full Text] [Related]
16. Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARgamma) ligand.
Yu HN; Lee YR; Noh EM; Lee KS; Kim JS; Song EK; Han MK; Lee YC; Kwon KB; Lee SJ; Youn HJ; Jung SH
Cell Biol Int; 2008 Aug; 32(8):906-12. PubMed ID: 18474441
[TBL] [Abstract][Full Text] [Related]
17. Rosiglitazone inhibits cell proliferation by inducing G1 cell cycle arrest and apoptosis in ADPKD cyst-lining epithelia cells.
Liu Y; Dai B; Fu L; Jia J; Mei C
Basic Clin Pharmacol Toxicol; 2010 Jun; 106(6):523-30. PubMed ID: 20210794
[TBL] [Abstract][Full Text] [Related]
18. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1.
Copland JA; Marlow LA; Kurakata S; Fujiwara K; Wong AK; Kreinest PA; Williams SF; Haugen BR; Klopper JP; Smallridge RC
Oncogene; 2006 Apr; 25(16):2304-17. PubMed ID: 16331265
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF
Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterisation of a prototype for a new class of competitive PPARγ antagonists.
Knape T; Flesch D; Kuchler L; Sha LK; Giegerich AK; Labocha S; Ferreirós N; Schmid T; Wurglics M; Schubert-Zsilavecz M; Proschak E; Brüne B; Parnham MJ; von Knethen A
Eur J Pharmacol; 2015 May; 755():16-26. PubMed ID: 25746464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
